Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05186974 · ClinicalTrials.gov registry record · Phase 2
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 2
- Development phase
- 193
- Enrollment target
- 20
- Study locations
NCT05186974 is a Phase 2 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 193 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05186974, a Phase 2 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 193 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Sacituzumab Govitecan-hziy (SG)
Study Locations (20)
California
- Beverly Hills Cancer Center - Beverly Hills
- USC/Norris Comprehensive Cancer Center - Los Angeles
- UCLA Hematology/Oncology - Santa Monica - Los Angeles
- UC Irvine Health - Orange
- Stanford Cancer Institute - Stanford
Illinois
- Northwestern Memorial Hospital - Chicago
- Rush University Medical Center - Chicago
- Orchard Healthcare Research Inc. - Skokie
New York
- Weill Cornell Medical/New York-Presbyterian Hospital - New York
- Great Lakes Cancer Care - Williamsville
North Carolina
- Wake Forest Baptist Health - High Point Medical Center - High Point
- FirstHealth Outpatient Cancer Center - Pinehurst
Alaska
- Alaska Oncology and Hematology, LLC. - Anchorage
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) - Aurora
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2022-05-30 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05186974
The ClinicalTrials.gov registry entry for NCT05186974 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (71% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05186974 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT05186974 about?
NCT05186974 is a clinical study titled "Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)". The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-ce...
What is the current status of trial NCT05186974?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 193 participants. The study started on 2022-05-30. Estimated completion is 2026-09.
What conditions does trial NCT05186974 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05186974?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Sacituzumab Govitecan-hziy (SG) (DRUG).
Who is sponsoring clinical trial NCT05186974?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05186974 being conducted?
This trial has 20 study locations across Alaska, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.